Calcified Tissue International

, 83:425

Characterization of the Bone Phenotype in ClC-7-Deficient Mice

  • Anita Vibsig Neutzsky-Wulff
  • Morten A. Karsdal
  • Kim Henriksen
Article

Abstract

Mice deficient in the chloride channel ClC-7, which is likely involved in acidification of the resorption lacuna, display severe osteopetrosis. To fully characterize the osteopetrotic phenotype, the phenotypes of osteoclasts and osteoblasts were evaluated. ClC-7−/− mice and their corresponding wild-type littermates were killed at 4–5 weeks of age. Biochemical markers of bone resorption (CTX-I), osteoclast number (TRAP5b), and osteoblast activity (ALP) were evaluated in serum. Splenocytes were differentiated into osteoclasts using M-CSF and RANKL. Mature osteoclasts were seeded on calcified or decalcified bone slices, and CTX-I, Ca2+, and TRAP were measured. Acidification rates in membrane vesicles from bone cells were measured using acridine orange. Osteoblastogenesis and nodule formation in vitro were investigated using calvarial osteoblasts. ClC-7−/− osteoclasts were unable to resorb calcified bone in vitro. However, osteoclasts were able to degrade decalcified bone. Acid influx in bone membrane vesicles was reduced by 70% in ClC-7−/− mice. Serum ALP was increased by 30% and TRAP5b was increased by 250% in ClC-7−/− mice, whereas the CTX/TRAP5b ratio was reduced to 50% of the wild-type level. Finally, evaluation of calvarial ClC-7−/− osteoblasts showed normal osteoblastogenesis. In summary, we present evidence supporting a pivotal role for ClC-7 in acidification of the resorption lacuna and evidence indicating that bone formation and bone resorption are no longer balanced in ClC-7−/− mice.

Keywords

ClC-7 Clcn7 Acidification Osteopetrosis Osteoclast Coupling 

References

  1. 1.
    Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121–125PubMedCrossRefGoogle Scholar
  2. 2.
    Martin TJ, Rodan GA (2001) Coupling of bone resorption and formation during bone remodeling. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic Press, San Diego, pp 361–370Google Scholar
  3. 3.
    Goltzman D (2002) Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov 1:784–796PubMedCrossRefGoogle Scholar
  4. 4.
    Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649PubMedCrossRefGoogle Scholar
  5. 5.
    Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229–1241PubMedCrossRefGoogle Scholar
  6. 6.
    Henriksen K, Sorensen MG, Nielsen RH, Gram J, Schaller S, Dziegiel MH, Everts V, Bollerslev J, Karsdal MA (2006) Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification. J Bone Miner Res 21:58–66PubMedCrossRefGoogle Scholar
  7. 7.
    Baron R, Neff L, Louvard D, Courtoy PJ (1985) Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101:2210–2222PubMedCrossRefGoogle Scholar
  8. 8.
    Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245:855–857PubMedCrossRefGoogle Scholar
  9. 9.
    Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, Keeling DJ, Andersson AK, Wallbrandt P, Zecca L, Notarangelo LD, Vezzoni P, Villa A (2000) Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 25:343–346PubMedCrossRefGoogle Scholar
  10. 10.
    Vaananen HK, Karhukorpi EK, Sundquist K, Wallmark B, Roininen I, Hentunen T, Tuukkanen J, Lakkakorpi P (1990) Evidence for the presence of a proton pump of the vacuolar H+-ATPase type in the ruffled borders of osteoclasts. J Cell Biol 111:1305–1311PubMedCrossRefGoogle Scholar
  11. 11.
    Jentsch TJ (2007) Chloride and the endosomal–lysosomal pathway: emerging roles of CLC chloride transporters. J Physiol 578:633–640PubMedCrossRefGoogle Scholar
  12. 12.
    Jentsch TJ, Stein V, Weinreich F, Zdebik AA (2002) Molecular structure and physiological function of chloride channels. Physiol Rev 82:503–568PubMedGoogle Scholar
  13. 13.
    Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G, Jentsch TJ (2001) Loss of the ClC–7 chloride channel leads to osteopetrosis in mice and man. Cell 104:205–215PubMedCrossRefGoogle Scholar
  14. 14.
    Jentsch TJ, Neagoe I, Scheel O (2005) CLC chloride channels and transporters. Curr Opin Neurobiol 15:319–325PubMedCrossRefGoogle Scholar
  15. 15.
    Accardi A, Miller C (2004) Secondary active transport mediated by a prokaryotic homologue of ClC Cl channels. Nature 427:803–807PubMedCrossRefGoogle Scholar
  16. 16.
    Picollo A, Pusch M (2005) Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436:420–423PubMedCrossRefGoogle Scholar
  17. 17.
    Scheel O, Zdebik AA, Lourdel S, Jentsch TJ (2005) Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 436:424–427PubMedCrossRefGoogle Scholar
  18. 18.
    Graves AR, Curran PK, Smith CL, Mindell JA (2008) The Cl/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788–792PubMedCrossRefGoogle Scholar
  19. 19.
    Lange PF, Wartosch L, Jentsch TJ, Fuhrmann JC (2006) ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and lysosomal function. Nature 440:220–223PubMedCrossRefGoogle Scholar
  20. 20.
    Balemans W, Van Wesenbeeck L, Van Hul W (2005) A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int 77:263–274PubMedCrossRefGoogle Scholar
  21. 21.
    Helfrich MH (2003) Osteoclast diseases. Microsc Res Tech 61:514–532PubMedCrossRefGoogle Scholar
  22. 22.
    Ogbureke KU, Zhao Q, Li YP (2005) Human osteopetroses and the osteoclast V-H+-ATPase enzyme system. Front Biosci 10:2940–2954PubMedCrossRefGoogle Scholar
  23. 23.
    Tolar J, Teitelbaum SL, Orchard PJ (2004) Osteopetrosis. N Engl J Med 351:2839–2849PubMedCrossRefGoogle Scholar
  24. 24.
    Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, Andolina M, Flanagan A, Horwitz EM, Mihci E, Notarangelo LD, Ramenghi U, Teti A, Van Hove J, Vujic D, Young T, Albertini A, Orchard PJ, Vezzoni P, Villa A (2003) Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res 18:1740–1747PubMedCrossRefGoogle Scholar
  25. 25.
    Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Vaananen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890PubMedCrossRefGoogle Scholar
  26. 26.
    Bollerslev J, Steiniche T, Melsen F, Mosekilde L (1989) Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 10:19–24PubMedCrossRefGoogle Scholar
  27. 27.
    Del Fattore A, Peruzzi B, Rucci N, Recchia I, Cappariello A, Longo M, Fortunati D, Ballanti P, Iacobini M, Luciani M, Devito R, Pinto R, Caniglia M, Lanino E, Messina C, Cesaro S, Letizia C, Bianchini G, Fryssira H, Grabowski P, Shaw N, Bishop N, Hughes D, Kapur RP, Datta HK, Taranta A, Fornari R, Migliaccio S, Teti A (2006) Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315–325PubMedCrossRefGoogle Scholar
  28. 28.
    Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K (2007) Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 22:487–494PubMedCrossRefGoogle Scholar
  29. 29.
    Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476PubMedGoogle Scholar
  30. 30.
    Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K (2008) Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366:483–488PubMedCrossRefGoogle Scholar
  31. 31.
    Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76–81PubMedCrossRefGoogle Scholar
  32. 32.
    Kasper D, Planells-Cases R, Fuhrmann JC, Scheel O, Zeitz O, Ruether K, Schmitt A, Poet M, Steinfeld R, Schweizer M, Kornak U, Jentsch TJ (2005) Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J 24:1079–1091PubMedCrossRefGoogle Scholar
  33. 33.
    Winding B, NicAmhlaoibh R, Misander H, Hoegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brunner N, Delaisse JM (2002) Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8:1932–1939PubMedGoogle Scholar
  34. 34.
    Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA (2007) Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA 104:16898–16903PubMedCrossRefGoogle Scholar
  35. 35.
    Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, Danielsen I, Christiansen C, Qvist P, Karsdal MA (2006) Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 14:738–748PubMedCrossRefGoogle Scholar
  36. 36.
    Edwards JC, Cohen C, Xu W, Schlesinger PH (2006) c-Src control of chloride channel support for osteoclast HCl transport and bone resorption. J Biol Chem 281:28011–28022PubMedCrossRefGoogle Scholar
  37. 37.
    Sorensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA (2007) Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 22:1640–1648PubMedCrossRefGoogle Scholar
  38. 38.
    Henriksen K, Karsdal M, Delaisse JM, Engsig MT (2003) RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278:48745–48753PubMedCrossRefGoogle Scholar
  39. 39.
    Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, Delaisse JM, Foged NT (2003) Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975–44987PubMedCrossRefGoogle Scholar
  40. 40.
    Henriksen K, Gram J, Høegh-Andersen P, Jemtland R, Ueland T, Dziegiel MH, Schaller S, Bollerslev J, Karsdal MA (2005) Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivo. Am J Pathol 167:1341–1348PubMedGoogle Scholar
  41. 41.
    Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C, Karsdal MA (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18:681–685PubMedCrossRefGoogle Scholar
  42. 42.
    Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, Beaverson K, Aledo A, Whyte MP, Yoneyama T, De Vernejoul MC, Van Hul W (2001) Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 10:2861–2867PubMedCrossRefGoogle Scholar
  43. 43.
    Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ (2003) Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res 18:1513–1518PubMedCrossRefGoogle Scholar
  44. 44.
    Henriksen K, Gram J, Schaller S, Dahl BH, Dziegiel MH, Bollerslev J, Karsdal MA (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537–1545PubMedGoogle Scholar
  45. 45.
    Chu K, Snyder R, Econs MJ (2006) Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties. J Bone Miner Res 21:1089–1097PubMedCrossRefGoogle Scholar
  46. 46.
    Blair HC, Borysenko CW, Villa A, Schlesinger PH, Kalla SE, Yaroslavskiy BB, Garcia-Palacios V, Oakley JI, Orchard PJ (2004) In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects. J Bone Miner Res 19:1329–1338PubMedCrossRefGoogle Scholar
  47. 47.
    Letizia C, Taranta A, Migliaccio S, Caliumi C, Diacinti D, Delfini E, D’Erasmo E, Iacobini M, Roggini M, Albagha OM, Ralston SH, Teti A (2004) Type II benign osteopetrosis (Albers-Schonberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations. Calcif Tissue Int 74:42–46PubMedCrossRefGoogle Scholar
  48. 48.
    Nielsen RH, Karsdal MA, Sorensen MG, Dziegiel MH, Henriksen K (2007) Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival. Biochem Biophys Res Commun 360:834–839PubMedCrossRefGoogle Scholar
  49. 49.
    Bollerslev J, Marks SC Jr, Pockwinse S, Kassem M, Brixen K, Steiniche T, Mosekilde L (1993) Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865–869PubMedCrossRefGoogle Scholar
  50. 50.
    Blair HC, Teitelbaum SL, Tan HL, Koziol CM, Schlesinger PH (1991) Passive chloride permeability charge coupled to H+-ATPase of avian osteoclast ruffled membrane. Am J Physiol Cell Physiol 260:C1315–C1324Google Scholar
  51. 51.
    Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA (2004) The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144–1153PubMedCrossRefGoogle Scholar
  52. 52.
    Graves AR, Curran PK, Smith CL, Mindell JA (2008) The Cl/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes. Nature 453:788–792PubMedCrossRefGoogle Scholar
  53. 53.
    Garnero P, Ferreras M, Karsdal MA, NicAmhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18:859–867PubMedCrossRefGoogle Scholar
  54. 54.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E (2005) Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159–172PubMedCrossRefGoogle Scholar
  55. 55.
    Delaisse JM, Engsig MT, Everts V, del Carmen OM, Ferreras M, Lund L, Vu TH, Werb Z, Winding B, Lochter A, Karsdal MA, Troen T, Kirkegaard T, Lenhard T, Heegaard AM, Neff L, Baron R, Foged NT (2000) Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta 291:223–234PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Anita Vibsig Neutzsky-Wulff
    • 1
  • Morten A. Karsdal
    • 1
  • Kim Henriksen
    • 1
  1. 1.Nordic Bioscience A/SHerlevDenmark

Personalised recommendations